Article info
PDFExtended report
A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis
- Correspondence to:
Dr Paul P Tak
Division of Clinical Immunology and Rheumatology F4–218, Academic Medical Centre, PO Box 22700, 1100 DE Amsterdam, Netherlands; p.p.takamc.uva.nl
Citation
A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis
Publication history
- Accepted May 9, 2004
- First published July 8, 2004.
Online issue publication
December 17, 2004
Article Versions
- Previous version (8 July 2004).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright 2005 by Annals of the Rheumatic Diseases